These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6983101)

  • 1. [Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods].
    Trouillas P; Garde A; Robert JM; Renaud B; Adeleine P; Bard J; Brudon F
    Rev Neurol (Paris); 1982; 138(5):415-35. PubMed ID: 6983101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
    Trouillas P
    Ital J Neurol Sci; 1984 Sep; 5(3):253-66. PubMed ID: 6334064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan].
    Trouillas P; Garde A; Robert JM; Adeleine P
    C R Seances Acad Sci III; 1981 Jan; 292(1):119-22. PubMed ID: 6786764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of chronic 5-hydroxy-tryptophan in parkinsonian instability of gait and balance and in other neurological disorders.
    Klein P; Lees A; Stern G
    Adv Neurol; 1987; 45():603-4. PubMed ID: 3493632
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of buspirone, a serotonergic 5-HT-1A agonist in cerebellar ataxia: a pilot study. Preliminary communication].
    Trouillas P; Xie J; Getenet JC; Adeleine P; Nighoghossian N; Honnorat J; Riche G; Derex L
    Rev Neurol (Paris); 1995 Dec; 151(12):708-13. PubMed ID: 8787101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases.
    Wessel K; Hermsdörfer J; Deger K; Herzog T; Huss GP; Kömpf D; Mai N; Schimrigk K; Wittkämper A; Ziegler W
    Arch Neurol; 1995 May; 52(5):451-5. PubMed ID: 7733838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An update on neurochemistry and pharmacological therapy of the cerebellar ataxias].
    Gazulla J
    Rev Neurol; 2007 Jul 1-15; 45(1):31-41. PubMed ID: 17620264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Physostigmine in treatment of cerebellar ataxia].
    Aschoff JC; Kailer NA; Walter K
    Nervenarzt; 1996 Apr; 67(4):311-8. PubMed ID: 8684510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels.
    Young SN; Gauthier S; Chouinard G; Anderson GM; Purdy WC
    J Neural Transm; 1982; 53(1):83-7. PubMed ID: 6801200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of substances modifying serotonin metabolism in the treatment of narco-cataplexy (considerations on 5 cases)].
    Testa G; Saia A; Chemello R
    Riv Neurol; 1979; 49(1):62-71. PubMed ID: 451399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Buspirone in the treatment of cerebellar ataxia].
    Svetel M; Vojvodić N; Filipović SR; Dragasević N; Sternić N; Kostić VS
    Srp Arh Celok Lek; 1999; 127(9-10):312-5. PubMed ID: 10649900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa.
    Thal L; Sharpless N; Wolfson L; Engel J; Katzman R
    Trans Am Neurol Assoc; 1976; 101():48-52. PubMed ID: 1088459
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of fast single-joint and multijoint movements in cerebellar cortical atrophy: failure of L-hydroxytryptophan to improve cerebellar ataxia.
    Manto M; Hildebrand J; Godaux E; Roland H; Blum S; Jacquy J
    Arch Neurol; 1997 Oct; 54(10):1192-4. PubMed ID: 9341562
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel approach for treating cerebellar ataxias.
    Manto M; Ben Taib NO
    Med Hypotheses; 2008; 71(1):58-60. PubMed ID: 18281160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebeller ataxia.
    Trouillas P
    Arch Neurol; 1990 Jan; 47(1):12. PubMed ID: 2403786
    [No Abstract]   [Full Text] [Related]  

  • 16. [Phosphatidylcholine in the treatment of degenerative spinocerebellar ataxic syndromes. Long-term study of 6 patients].
    De Luca G; Sottile G; Nastasi G; Casaceli A
    Riv Neurol; 1983; 53(6):392-9. PubMed ID: 6669885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment.
    du Montcel ST; Charles P; Ribai P; Goizet C; Le Bayon A; Labauge P; Guyant-Maréchal L; Forlani S; Jauffret C; Vandenberghe N; N'guyen K; Le Ber I; Devos D; Vincitorio CM; Manto MU; Tison F; Hannequin D; Ruberg M; Brice A; Durr A
    Brain; 2008 May; 131(Pt 5):1352-61. PubMed ID: 18378516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients.
    Matussek N; Angst J; Benkert O; Gmür M; Papousek M; Rüther E; Woggon B
    Adv Biochem Psychopharmacol; 1974; 11(0):399-404. PubMed ID: 4602669
    [No Abstract]   [Full Text] [Related]  

  • 19. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing.
    Trouillas P; Brudon F; Adeleine P
    Arch Neurol; 1988 Nov; 45(11):1217-22. PubMed ID: 3190503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability and validity of ICARS in focal cerebellar lesions.
    Schoch B; Regel JP; Frings M; Gerwig M; Maschke M; Neuhäuser M; Timmann D
    Mov Disord; 2007 Nov; 22(15):2162-9. PubMed ID: 17712842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.